Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MEDI8897

- PMLiVE

Denmark pitches for EMA, with help from ex Novo Nordisk CEO

Lars Rebien Sørensen to serve as special envoy to promote Danish candidacy

- PMLiVE

Amgen’s chronic kidney disease drug Parsabiv cleared in US

Sensipar follow-up is the first therapy to be approved for treatment of sHPT in 12 years

- PMLiVE

Biotech leaders slam Trump over immigration order

Former Teva CEO Jeremy Levin heads open letter expressing “deep concern and opposition”

- PMLiVE

Cello Health expands with Defined Health acquisition

Builds US presence with biotech-focused strategy specialist

- PMLiVE

Promoting off-label use: where to draw the line?

Looking at the trend among EU member states to actively promote the off-label use of medicines

- PMLiVE

Trump talks pricing and manufacturing with pharma

Heads of Celgene, Lilly, Merck & Co, Novartis and trade body PhRMA met at the White House

- PMLiVE

Amgen’s Humira biosimilars backed for EU approval

Amgevita and Solymbic prepare to challenge AbbVie’s blockbuster

- PMLiVE

Merck settles PD-1 patent lawsuit with BMS and Ono

Agrees to pay $625m settlement plus royalties on sales of Keytruda until 2026

- PMLiVE

The impact of Trump’s victory on pharma and healthcare

Donald Trump’s presidency is unlikely to leave any industry untouched. But how will pharma, biotech and healthcare fare when he takes office?

Sanofi reception

Sanofi wins EU approval for new diabetes combination Suliqua

European Commission licenses the once-daily version of Lantus and Lyxumia

UK flag

May says UK’s science base is a “negotiating priority” for Brexit

Stokes confidence in UK pharma as science and innovation featured among 12 key priorities

Allergan logo

Allergan plans to file oral uterine fibroid drug in US by year-end

Analysts predict treatment will reach blockbuster sales as phase III trials meet objectives

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links